Evidence map›Paper›PMID 42883170›Full record

ReviewMolecules (Basel, Switzerland)2026

Reimagining Cannabidiol Delivery Through Carbon Nanodots.

Iddrisu Ibrahim, Kelci Lawrence, Othreniel Angel Forte, Navitri Chandra Naidu, Latrell Huitt, Nathaniel Ajibola, Junhuan Xu, Robertson K Boakai, Moses Mengu, Fortune Akabanda and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Iddrisu IbrahimThe Microbiology Program, College of Science, Technology, Engineering, and Mathematics (C-STEM), Alabama State University, Montgomery, AL 36104, USA.ORCID 0000-0002-9058-1616
Kelci LawrenceThe Microbiology Program, College of Science, Technology, Engineering, and Mathematics (C-STEM), Alabama State University, Montgomery, AL 36104, USA.
Othreniel Angel ForteThe Microbiology Program, College of Science, Technology, Engineering, and Mathematics (C-STEM), Alabama State University, Montgomery, AL 36104, USA.ORCID 0009-0003-2001-985X
Navitri Chandra NaiduThe Microbiology Program, College of Science, Technology, Engineering, and Mathematics (C-STEM), Alabama State University, Montgomery, AL 36104, USA.
Latrell HuittThe Microbiology Program, College of Science, Technology, Engineering, and Mathematics (C-STEM), Alabama State University, Montgomery, AL 36104, USA.
Nathaniel AjibolaThe Microbiology Program, College of Science, Technology, Engineering, and Mathematics (C-STEM), Alabama State University, Montgomery, AL 36104, USA.
Junhuan XuThe Microbiology Program, College of Science, Technology, Engineering, and Mathematics (C-STEM), Alabama State University, Montgomery, AL 36104, USA.
Robertson K BoakaiThe Microbiology Program, College of Science, Technology, Engineering, and Mathematics (C-STEM), Alabama State University, Montgomery, AL 36104, USA.
Moses MenguAfrican Drug Discovery and Innovation Network, Sunyani P.O. Box AB45, Ghana.
Fortune AkabandaDepartment of Food Science and Technology, University for Development Studies, Tamale P.O. Box TL1350, Ghana.ORCID 0000-0002-3118-7619
James Owusu-KwartengAfrican Drug Discovery and Innovation Network, Sunyani P.O. Box AB45, Ghana.ORCID 0000-0002-2703-3393
Olufemi S AjayiThe Microbiology Program, College of Science, Technology, Engineering, and Mathematics (C-STEM), Alabama State University, Montgomery, AL 36104, USA.ORCID 0000-0002-3556-803X
Joseph Atia AyarigaThe Microbiology Program, College of Science, Technology, Engineering, and Mathematics (C-STEM), Alabama State University, Montgomery, AL 36104, USA.ORCID 0000-0003-4561-8245

Funding

United States Department of Education Title III-HBGI-RES
6 · The paper itself

Abstract

Cannabidiol (CBD) is a highly lipophilic phytocannabinoid whose low aqueous solubility, variable oral absorption, extensive first-pass metabolism, and chemical instability motivate advanced delivery strategies. Carbon nanodots (CNDs) have tunable surface chemistry and photoluminescence and have been investigated as carriers for multiple therapeutic cargos. This review critically evaluates whether the literature supports a specific CBD-CND delivery advantage. A structured narrative search of PubMed and targeted publisher websites was conducted. Evidence was classified as direct CBD-CND evidence, indirect CND-platform evidence, or indirect CBD-nanoformulation evidence. No direct study was identified that characterized CBD loading on CNDs and then demonstrated release, pharmacokinetics, safety, or therapeutic efficacy. Existing support is therefore indirect: CNDs can carry other drugs, whereas lipid, polymeric, micellar, and transdermal systems can improve selected CBD formulation or preclinical endpoints. Consequently, improved solubility, targeting, lower toxicity, enhanced bioavailability, and therapeutic synergy remain hypotheses for CBD-CND systems. The review retains a broad discussion of possible applications while clearly separating demonstrated evidence from proposed uses and defining the analytical, comparative, pharmacokinetic, biodistribution, and toxicological studies needed to validate the platform.

Indexed as

CannabidiolCarbonCarbon Quantum DotsDrug CarriersDrug Delivery SystemsAnimalsHumansSolubilityCannabidiolCarbonDrug Carrierscannabidiolcarbon nanodotsdrug deliveryevidence classificationnanocarrierspharmacokineticssafetytargeting

Identifiers

PMID42883170
PMCPMC13666312

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.